Immunotherapy for gynaecological malignancies

被引：28

作者：

Coukos, G ^{[1
]}

Conejo-Garcia, JR

Roden, RBS

Wu, TC

机构：

[1] Univ Penn, Abramson Canc Res Inst, Philadelphia, PA 19104 USA

[2] Univ Penn, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2005年 / 5卷 / 09期

关键词：

cervical cancer; cytokine; HPV; immunotherapy; lymphocyte; ovarian cancer; tumour-infiltrating; vaccine development;

D O I：

10.1517/14712598.5.9.1193

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Gynaecological malignancies, excluding breast cancer, cause similar to 25,000 deaths yearly among women in the US. Therefore, novel approaches for the prevention or treatment of these diseases are urgently required. In the case of cervical cancer, human papillomavirus (HPV) xenciantigens are readily recognised by the immune system, and their targeting has shown great promise in preclinical models of therapeutic vaccination and in clinical studies of peventative vaccination. A growing body of evidence indicates that ovarian cancer is also immunogenic and can thus be targeted through immunotherapy. This review outlines the principles and problems of immunotherapy for cervical and ovarian cancer, including the authors' personal assessment.

引用

页码：1193 / 1210

页数：18

共 219 条

[1] Dendritic cell (DC) based therapy for cervical cancer:: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C12U] (Ampligen®) [J].

Adams, M ;

Navabi, H ;

Jasani, B ;

Man, S ;

Fiander, A ;

Evans, AS ;

Donninger, C ;

Mason, M .

VACCINE, 2003, 21 (7-8) :787-790

[2] Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer [J].

Adams, M ;

Borysiewicz, L ;

Fiander, A ;

Man, S ;

Jasani, B ;

Navabi, H ;

Lipetz, C ;

Evans, AS ;

Mason, M .

VACCINE, 2001, 19 (17-19) :2549-2556

[3] Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN [J].

Ahonen, CL ;

Doxsee, CL ;

McGurran, SM ;

Riter, TR ;

Wade, WF ;

Barth, RJ ;

Vasilakos, JP ;

Noelle, RJ ;

Kedl, RM .

JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (06) :775-784

[4] Tumor-specific killer cells in paraneoplastic cerebellar degeneration [J].

Albert, ML ;

Darnell, JC ;

Bender, A ;

Francisco, LM ;

Bhardwaj, N ;

Darnell, RB .

NATURE MEDICINE, 1998, 4 (11) :1321-1324

[5] Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes [J].

Albert, ML ;

Pearce, SFA ;

Francisco, LM ;

Sauter, B ;

Roy, P ;

Silverstein, RL ;

Bhardwaj, N .

JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (07) :1359-1368

[6] THE YIN AND YANG OF T-CELL COSTIMULATION [J].

ALLISON, JP ;

KRUMMEL, MF .

SCIENCE, 1995, 270 (5238) :932-933

[7]

Andersen MH, 2002, HISTOL HISTOPATHOL, V17, P669, DOI 10.14670/HH-17.669

[8]

[Anonymous], [No title captured]

[9]

[Anonymous], 1992, PAPILLOMAVIRUS REP

[10] ACTIVE SPECIFIC IMMUNOTHERAPY WITH VACCINIA COLON ONCOLYSATE ENHANCES THE IMMUNOMODULATORY AND ANTITUMOR EFFECTS OF INTERLEUKIN-2 AND INTERFERON-ALPHA IN A MURINE HEPATIC METASTASIS MODEL [J].

ARROYO, PJ ;

BASH, JA ;

WALLACK, MK .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 1990, 31 (05) :305-311

← 1 2 3 4 5 6 7 8 9 10 →